Boehringer Ingelheim Reports 22% more 'Satisfying Sexual Events' Than Placebo

RoseTracker| Women who took Boehringer Ingelheim GmbH’s desire drug pill, known as flibanserin, reported 22 percent more “satisfying sexual events” than those given a placebo in two clinical tests of 1,378 patients, according to abstracts released today at the European Society for Sexual Medicine annual meeting in Lyon, France.

The most positive response came among American women, suggesting that cultural and physiological factors are also at play in the study of female sexual desire. No surprises there. Read on in Sensual and Superyoung.